Distinguished in Inflammatory Breast Cancer

Dr. Alexandra K. Thomas

Hematology Oncology | Hematology | Oncology
Duke Health
Duke Health Integrated Practice Inc
20 Duke Medicine Cir, 
Durham, NC 
Clinical Trials:Currently Recruiting for 2 Trials
Accepting New Patients
Offers Telehealth
Distinguished in Inflammatory Breast Cancer
Duke Health
Duke Health Integrated Practice Inc
20 Duke Medicine Cir, 
Durham, NC 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Alexandra Thomas is a Hematologist Oncology specialist and a Hematologist in Durham, North Carolina. Dr. Thomas is rated as a Distinguished provider by MediFind in the treatment of Inflammatory Breast Cancer. Her top areas of expertise are Angiosarcoma, Breast Cancer, Inflammatory Breast Cancer, and Paget Disease of the Breast. Dr. Thomas is currently accepting new patients.

Her clinical research consists of participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in IA
Hospital Affiliations
Duke University Hospital
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Alignment Health Plan
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
AmeriHealth
  • EPO
  • HMO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Medica
  • EPO
  • HMO
  • PPO
Oscar
  • EPO
  • HMO
  • PPO
Sentara Healthcare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE ASSISTANCE PROGRAM
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 13 Less Insurance Carriers -

Locations

DUKE HEALTH INTEGRATED PRACTICE INC
20 Duke Medicine Cir, Durham, NC 27710
Call: 919-684-8111

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

I-SPY Trial (Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging And moLecular Analysis 2)
I-SPY Trial (Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging And moLecular Analysis 2)
Enrollment Status: Recruiting
Publish Date: January 28, 2026
Intervention Type: Drug
Study Drugs: Standard Therapy, AMG 386 +/- Trastuzumab, AMG 479 (Ganitumab)+Metformin, MK-2206 +/- Trastuzumab, AMG 386+Trastuzumab, T-DM1+Pertuzumab, Pertuzumab+Trastuzumab, Ganetespib, ABT-888, Neratinib, PLX3397, Pembrolizumab - 4 Cycle, Talazoparib+Irinotecan, Patritumab+Trastuzumab, Pembrolizumab - 8 Cycle, SGN-LIV1A, Durvalumab+Olaparib, SD-101+Pembrolizumab, Tucatinib+Trastuzumab and Pertuzumab, Cemiplimab, Cemiplimab+REGN3767, Trilaciclib +/- Trastuzumab+Pertuzumab, SYD985 ([vic-]Trastuzumab Duocarmazine), Oral Paclitaxel+Encequidar+Dostarlimab (TSR-042)+Carboplatin +/- Trastuzumab, Oral Paclitaxel+Encequidar+Dostarlimab (TSR-042) +/- Trastuzumab
Study Phase: Phase 2
Oral Aromatase Inhibitors Modify the Gut Microbiome Effecting Estrogen Bioavailability
Oral Aromatase Inhibitors Modify the Gut Microbiome Effecting Estrogen Bioavailability
Enrollment Status: Recruiting
Publish Date: November 14, 2025
Intervention Type: Biological
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Other, Radiation, Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 3
The ESPRIT Study: Estrogen Suppression and Perfusion Reserve With Aromatase-Inhibitor Treatment in Premenopausal Women With Breast Cancer
The ESPRIT Study: Estrogen Suppression and Perfusion Reserve With Aromatase-Inhibitor Treatment in Premenopausal Women With Breast Cancer
Enrollment Status: Completed
Publish Date: January 29, 2026
Intervention Type: Procedure, Biological, Drug
A Randomized Phase III Trial of Endocrine Therapy Plus Entinostat/Placebo in Patients With Hormone Receptor-Positive Advanced Breast Cancer
A Randomized Phase III Trial of Endocrine Therapy Plus Entinostat/Placebo in Patients With Hormone Receptor-Positive Advanced Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 18, 2025
Intervention Type: Other, Procedure, Drug
Study Drugs: Entinostat, Exemestane, Goserelin, Goserelin Acetate
Study Phase: Phase 3
A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 2 Study of Atezolizumab With or Without Entinostat in Patients With Advanced Triple Negative Breast Cancer, With a Phase 1b Lead in Phase
A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 2 Study of Atezolizumab With or Without Entinostat in Patients With Advanced Triple Negative Breast Cancer, With a Phase 1b Lead in Phase
Enrollment Status: Completed
Publish Date: December 04, 2024
Intervention Type: Drug
Study Drugs: Entinostat, Atezolizumab
Study Phase: Phase 1/Phase 2
A Phase I Study of ASTX727 Plus Talazoparib in Patients With Triple Negative or Hormone Resistant/ Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Metastatic Breast Cancer
A Phase I Study of ASTX727 Plus Talazoparib in Patients With Triple Negative or Hormone Resistant/ Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Metastatic Breast Cancer
Enrollment Status: Completed
Publish Date: March 22, 2024
Intervention Type: Drug
Study Drugs: Talazoparib, ASTX727
Study Phase: Phase 1
ISPY-P1.01: Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer: A Phase I/Ib Trial
ISPY-P1.01: Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer: A Phase I/Ib Trial
Enrollment Status: Withdrawn
Publish Date: November 18, 2023
Intervention Type: Drug
Study Phase: Phase 1
Inhibiting Fatty Acid Synthase to Improve Efficacy of Neoadjuvant Chemotherapy
Inhibiting Fatty Acid Synthase to Improve Efficacy of Neoadjuvant Chemotherapy
Enrollment Status: Completed
Publish Date: December 15, 2021
Intervention Type: Drug
Study Drugs: chemotherapy, Omeprazole
Study Phase: Phase 2
View 7 Less Clinical Trials
Similar Doctors
Distinguished in Inflammatory Breast Cancer
Dr. Jeremy M. Force
Hematology Oncology | Hematology | Oncology
Distinguished in Inflammatory Breast Cancer
Dr. Jeremy M. Force
Hematology Oncology | Hematology | Oncology
10 Bryan Searle Drive Seeley Mudd Building Room 449b, 
Durham, NC 
 (2.2 miles away)
919-613-6891
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Jeremy Force is a Hematologist Oncology specialist and a Hematologist in Durham, North Carolina. Dr. Force is rated as a Distinguished provider by MediFind in the treatment of Inflammatory Breast Cancer. His top areas of expertise are Breast Cancer, Inflammatory Breast Cancer, Paget Disease of the Breast, and Angiosarcoma. Dr. Force is currently accepting new patients.

Distinguished in Inflammatory Breast Cancer
Dr. Mark L. Graham
Hematology Oncology | Hematology | Oncology
Distinguished in Inflammatory Breast Cancer
Dr. Mark L. Graham
Hematology Oncology | Hematology | Oncology

Wakemed Specialists Group LLC

210 Ashville Ave, 
Cary, NC 
 (20.2 miles away)
919-350-2800
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Mark Graham is a Hematologist Oncology specialist and a Hematologist in Cary, North Carolina. Dr. Graham is rated as a Distinguished provider by MediFind in the treatment of Inflammatory Breast Cancer. His top areas of expertise are Paget Disease of the Breast, Breast Cancer, Angiosarcoma, Bone Marrow Aspiration, and Endoscopy. Dr. Graham is currently accepting new patients.

Hyman B. Muss
Distinguished in Inflammatory Breast Cancer
Dr. Hyman B. Muss
Hematology Oncology | Hematology | Oncology
Distinguished in Inflammatory Breast Cancer
Dr. Hyman B. Muss
Hematology Oncology | Hematology | Oncology
143 W Franklin St, 
Chapel Hill, NC 
 (9.4 miles away)
919-966-4131
Languages Spoken:
English
See accepted insurances

Hyman Muss is a Hematologist Oncology specialist and a Hematologist in Chapel Hill, North Carolina. Dr. Muss is rated as a Distinguished provider by MediFind in the treatment of Inflammatory Breast Cancer. His top areas of expertise are Breast Cancer, Inflammatory Breast Cancer, Angiosarcoma, and Paget Disease of the Breast.

VIEW MORE INFLAMMATORY BREAST CANCER DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Thomas's expertise for a condition
ConditionClose
    • Distinguished
    • Angiosarcoma
      Dr. Thomas is
      Distinguished
      . Learn about Angiosarcoma.
      See more Angiosarcoma experts
    • Breast Cancer
      Dr. Thomas is
      Distinguished
      . Learn about Breast Cancer.
      See more Breast Cancer experts
    • Inflammatory Breast Cancer
      Dr. Thomas is
      Distinguished
      . Learn about Inflammatory Breast Cancer.
      See more Inflammatory Breast Cancer experts
    • Paget Disease of the Breast
      Dr. Thomas is
      Distinguished
      . Learn about Paget Disease of the Breast.
      See more Paget Disease of the Breast experts
      • Experienced
      • Breast Cancer in Men
        Dr. Thomas is
        Experienced
        . Learn about Breast Cancer in Men.
        See more Breast Cancer in Men experts
      • Intraductal Papilloma
        Dr. Thomas is
        Experienced
        . Learn about Intraductal Papilloma.
        See more Intraductal Papilloma experts
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile
      For Patients
      • Our Story
      • How MediFind Works
      • Conditions A-Z
      • Doctor Directory
      • Symptoms Directory
      • Procedures Directory
      • Treatment Directory
      • Drug Directory
      • Infusion Center Finder
      • FAQ
      • Contact Us
      For Providers and Practices
      • Claim Your Profile
      • Newsroom
      Business Solutions
      • Provider
      • Network Solutions
      Additional Resources
      • Consumer Health Data Privacy Policy
      • Privacy Policy
      • Terms of Use
      • Advertising Policy
      • Content Policy
      Subscribe to our newsletter

      Sign up to stay informed about MediFind and get wellness sent your way.

      Close

        By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

        Bullet PinMediFind
        Follow us on
        This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
        © 2026 All Rights Reserved

        Request an Appointment

        If you are experiencing a medical emergency, call 9-1-1.

        MediFind will contact the provider for your appointment request. You’ll receive status updates by email. Your provider or MediFind will reach out to you directly by phone or email to schedule your appointment or request additional information.

        Patient Details

        This information is for the patient who will be seen at the appointment.

          Close

          Returning patient? Use your address on file with the provider.

          Insurance Details

          Please provide information of the primary insurance holder as the practice may require this information to schedule.

          Insurance Provider *
          Insurance ProviderClose

          Appointments Details

          Let’s get more information about your appointment.

                  0 / 1000
                  0 / 1000
                  By pressing the Submit button you are agreeing to MediFind’s Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.